Aspire Private Capital’s United Therapeutics UTHR Stock Holding History

Aspire Private Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-26	Closed	-$9.32K	–	605
2024 Q3	$9.32K	Hold	26	–	–	﹤0.01%	390
2024 Q2	$8.28K	Hold	26	–	–	﹤0.01%	405
2024 Q1	$5.97K	Hold	26	–	–	﹤0.01%	464
2023 Q4	$5.72K	Hold	26	–	–	﹤0.01%	455
2023 Q3	$5.87K	Hold	26	–	–	﹤0.01%	462
2023 Q2	$5.74K	Hold	26	–	–	﹤0.01%	434
2023 Q1	$5.82K	Sell	26 -3	-10%	-$740	﹤0.01%	421
2022 Q4	$8.06K	Hold	29	–	–	﹤0.01%	379
2022 Q3	$6K	Sell	29 -2	-6%	-$447	﹤0.01%	408
2022 Q2	$7K	Hold	31	–	–	﹤0.01%	377
2022 Q1	$6K	Hold	31	–	–	﹤0.01%	389
2021 Q4	$7K	Sell	31 -2	-6%	-$393	﹤0.01%	383
2021 Q3	$6K	Hold	33	–	–	﹤0.01%	370
2021 Q2	$6K	Sell	33 -2	-6%	-$381	﹤0.01%	378
2021 Q1	$6K	Buy	35 +33	+1,650%	+$5.5K	﹤0.01%	373
2020 Q4	$0	Hold	2	–	–	﹤0.01%	536
2020 Q3	$0	Sell	2 -35	-95%	-$3.84K	﹤0.01%	512
2020 Q2	$4K	Buy	+37	New	+$4.16K	﹤0.01%	245

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Aspire Private Capital's UTHR Position: Q4 2024 in Review

Aspire Private Capital sold out of United Therapeutics (UTHR) in Q4 2024, closing a stake of 26 shares — an estimated $9.32K sold.

Aspire Private Capital first reported a position in UTHR in Q2 2020 and held it in 18 quarters. The position peaked at $9.32K in Q3 2024. 673 funds tracked by Wall St. Rank hold UTHR as of Q4 2024.

Aspire Private Capital reported no remaining United Therapeutics position as of Q4 2024 after selling out during the quarter.
Aspire Private Capital sold 26 United Therapeutics shares in Q4 2024, an estimated $9.32K.
Aspire Private Capital first reported a position in United Therapeutics in Q2 2020 and held it in 18 quarters.
Aspire Private Capital's United Therapeutics position peaked at $9.32K in Q3 2024.
673 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2024.

Based on Aspire Private Capital's 13F filing for Q4 2024, filed 17 Jan 2025.